PE-22-28 for Cognitive Enhancement & Neuroprotection — Brain
Synthetic peptide derived from phosphodiesterase inhibitor that enhances BDNF expression, neuroplasticity, and cognitive function.
Overview
PE-22-28 is a synthetic heptapeptide derived from the spadin-related peptide family, originally identified as a fragment with antidepressant-like and pro-cognitive activity in preclinical models. PE-22-28 enhances BDNF (Brain-Derived Neurotrophic Factor) expression by inhibiting TREK-1 potassium channels, a mechanism shared with spadin (the natural TREK-1 blocker). In mouse models, PE-22-28 demonstrated enhanced memory consolidation, improved spatial learning (Morris water maze), and antidepressant-like effects in forced swim tests, with potency comparable to SSRIs but without serotonergic side effects. Mazella et al. (British Journal of Pharmacology, 2010) established the TREK-1 channel as a novel antidepressant target. The peptide promotes hippocampal neurogenesis and synaptic plasticity through BDNF-TrkB signaling. NO human clinical trials have been conducted. All evidence is preclinical (rodent studies). NOT FDA-approved. Dosing is extrapolated from animal studies and user reports in the biohacking community. Available as a research compound only.
Indications
- Cognitive enhancement and memory consolidation (preclinical)
- Neuroprotection and neuroplasticity support
- Antidepressant-like effects via TREK-1 channel inhibition (preclinical)
- BDNF enhancement for brain health optimization
Mechanism of Action
Reduced BDNF signaling and TREK-1 channel overactivity contribute to impaired neuroplasticity and cognitive function
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| PE-22-28 | 100-300 mcg | Once daily (morning) | Intranasal route for direct CNS delivery; extrapolated from preclinical data |
| PE-22-28 | 200-500 mcg | Once daily | Subcutaneous route for systemic delivery; no validated human dosing |
Evidence Grade
GRADE D
Safety & Contraindications
- NO human clinical trials - all evidence is preclinical (rodent studies)
- Not FDA-approved; research compound only
- Unknown long-term safety profile in humans
- Potential interactions with antidepressants (TREK-1 modulation overlaps with SSRI targets)
- Use sterile technique for injectable formulations
- Requires medical supervision due to complete absence of human safety data